1207818261

Medical interventions for C0VID-19 - what we know and what we know we don’t know

What we already know

An effective anti-viral drug or vaccine is unlikely to be available before lockdown restrictions are relaxed	Despite unprecedented global collaboration and investment, an effective treatment for COVID-19 remains several months away. Potentially promising vaccines are targeting emergency use FDA authorisation from September 2020, but Phase III data is unlikely to be available until 2021.	Further detail page 5
We’re expecting to see first details on vaccine success in the summer	The most promising vaccine developments are mostly targeting preliminary results during the summer of 2020. If these prove to be successful then the path to a vaccine becomes clearer and emergency use authorisation may follow.	Further detail page 5
__

The most effective treatment for C0VID-19 patients is not yet elear. Currently being tested    The ITlOSt effective type of flOflarę: specific anti-virats, treatments to prevent cytokine storms or other damaging immune    VdCCifie medical intervention isn’t

system responses, and the use of common treatments such as corticosteroids.

yet known

Further detail page 6

The interest in potential treatments for COVID-19 has led to results being leaked from current clinical trials. This has generally indicated Iow clinical benefit, but it is hard to interpret as most of the data lacks statistical significance (due to either bias or sample size). One view that may emerge from this data is that the circumstances where treatments are effective could vary materially depending on specific patient circumstances.

It remains unclear whether currently trialled treatments will prove effective, and for which patients

Further detail page 7

The ability to test large numbers of people accurately remains a key enabler for effective control of

the pandemie under less strict restrictions. As yet, only RT-PCR tests have been shown to be    An effective and Cheap test for

sufficiently accurate. These are difficult to scalę and can only tell if a patient currently has COVID-19.    COVID-19 is Still to emerge

Roche recently received emergency approval from the FDA for an antibody test.

What we don’t know yet

4